NYSE:TROX

Analyst Sets Price Target for Tronox (NYSE: TROX) Amidst Mixed Financials

Font: Financial Modeling Prep  • Aug 13, 2026

Market Chart
  • An analyst set a price target of $5.00 for Tronox (NYSE: TROX), representing an 18.96% decrease from its prior stock price of $6.17.
  • Tronox reported revenues of $868 million in Q2 2026, beating analyst estimates, but its adjusted loss widened to $0.51 per share.
  • The company projects Q3 adjusted EBITDA to be between $95 million and $115 million, anticipating price increases to help improve results despite a seasonal decrease in sales volumes.

On August 13, 2026, an analyst from China Renaissance Securities (US) Inc. set a price target of $5.00 for Tronox (NYSE: TROX). Tronox is a leading global manufacturer of titanium dioxide pigment, a product used to make paints, plastics, and paper white. The new target is 18.96% below the stock's price of $6.17 at that time.

The analyst's view may reflect the company's mixed financial results. For its second quarter of 2026, Tronox reports revenues of $868 million, a 19% increase from the previous year. As highlighted by Zacks, this sales figure beat analyst estimates, driven by an 18% rise in titanium dioxide volumes and a 61% increase in zircon volumes.

Despite higher sales, profitability is a concern. The company's adjusted loss widened to $0.51 per share, which is greater than the prior year's loss of $0.28. This loss was also worse than the expected loss of $0.39 per share. The company states that higher production, freight, and other operational costs are the main reasons for the deeper loss.

The company’s adjusted EBITDA for the quarter was $73 million. EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is a measure of a company's operating profit. This results in an adjusted EBITDA margin of 8.4%, which shows how much operating profit Tronox makes for every dollar of revenue.

Looking ahead, Tronox expects adjusted EBITDA for the third quarter to be between $95 million and $115 million. The company anticipates that price increases for its products will help improve results. However, it also projects a moderate decrease in titanium dioxide sales volumes, which is a normal seasonal trend.

Market Overview
MDXH
MDxHealth S.A.
$0.91
97.73%
SURG
SurgePays, Inc.
$0.30
20.07%
VBIO
Valion Bio, Inc.
$0.20
19.09%
NU
Nu Holdings Ltd.
$15.16
8.79%
TSLL
Direxion Daily TSLA Bull 2X ETF
$8.74
1.10%
OTLK
Outlook Therapeutics, Inc.
$0.75
-15.34%
ONFO
Onfolio Holdings, Inc.
$2.80
21.21%
ONDS
Ondas Holdings Inc.
$9.11
2.19%
SPCX
Space Exploration Technologies Corp.
$139.50
-1.27%
CYCU
Cycurion, Inc. Common Stock
$0.66
-5.91%